Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Chemed Corporation’s (NYSE: CHE) SEC filings, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Chemed is a Delaware-incorporated holding company headquartered in Cincinnati, Ohio, operating VITAS Healthcare and Roto-Rooter as wholly owned subsidiaries.
For investors analyzing Chemed’s hospice operations, filings and related exhibits can offer detail on VITAS Healthcare’s net patient revenue, average daily census, admissions, and the impact of Medicare reimbursement rates and Medicare Cap billing limitations. Management’s discussion of these topics in earnings releases, which are often furnished as exhibits to Form 8-K, helps explain how regulatory and reimbursement factors influence segment performance.
Filings also shed light on Roto-Rooter’s plumbing, drain cleaning, water restoration, and water cleanup services. Segment disclosures in attached earnings releases describe revenue trends across commercial and residential customers, gross margins, selling, general and administrative expenses, and adjusted EBITDA margins. These details help readers understand how demand for plumbing and drain cleaning services affects Chemed’s consolidated results.
Chemed’s SEC filings may address capital structure and capital allocation, including its Amended and Restated Credit Agreement, share repurchase authorizations, and long-running dividend program. They can also disclose material events such as updates to earnings guidance, executive leadership changes, or other significant corporate developments.
On this page, AI-powered tools summarize lengthy filings and attached press releases, highlighting items such as quarterly earnings (often reported via Form 8-K), non-GAAP measures like EBITDA and Adjusted Diluted EPS, and regulatory or reimbursement disclosures relevant to VITAS and Roto-Rooter. Users can also review insider- and management-related information when it appears in current reports or other SEC documents.
Chemed Corp. director Andrea R. Lindell reported a small change in ownership. On 12/26/2025, Lindell disposed of 463 shares of Chemed capital stock in a transaction coded "G," which indicates a gift. Following this transfer, Lindell beneficially owns 5,539 shares of Chemed stock, held directly. This filing simply updates public records of insider ownership for the company.
Chemed filed a notice of proposed sale under Rule 144 covering 942 shares of its common stock. These shares are planned to be sold through UBS Financial Services Inc. on the NYSE, with an approximate sale date of 12/11/2025 and an aggregate market value of 405,645. The filing notes that 14,164,195 shares of common stock were outstanding, giving context for the size of this planned transaction. The seller acquired the 942 shares in a private transaction from Chemed on 12/01/2025 and paid for them on the same date.
Chemed Corp. insider Kevin J. McNamara, who serves as director, president and CEO, reported a sale of company stock. On 11/24/2025, he sold 2,000 shares of Chemed capital stock in an open market transaction coded as "S" for sale. The weighted average sale price was $437.55 per share, with individual trade prices ranging from $436.13 to $438.53.
After this transaction, McNamara beneficially owns 94,197 shares of Chemed stock in direct form. He has indicated a willingness to provide detailed breakdowns of the number of shares sold at each separate price within the reported range to Chemed, its security holders, or SEC staff upon request.
CHE has a Form 144 notice indicating a planned sale of 2,000 common shares. The shares are to be sold through Raymond James & Associates on or about 11/24/2025 on the NYSE, with an aggregate market value of $876,000. Shares outstanding were 14,110,000; this is a baseline figure, not the amount being sold.
The seller acquired the shares through stock awards from the issuer in 2016. The filing also lists prior sales over the past three months by Kevin J McNamara, including 1,000 common shares for gross proceeds of $460,647 and 2,000 common shares for $922,794, both on 09/26/2025. The signer represents they are not aware of undisclosed material adverse information about the issuer.
Chemed Corp executive vice president reports small share transfer
Chemed Corp executive vice president Spencer S. Lee reported a change in ownership of company stock. On 11/19/2025, Lee disposed of 60 shares of Chemed Corp capital stock in a transaction coded "G," which typically denotes a gift or similar transfer, at a reported price of $0.00 per share. After this transaction, Lee beneficially owns 14,567 shares directly.
Chemed (CHE) reported Q3 2025 results. Service revenues and sales were $624.9 million, up from $606.2 million a year ago. Net income was $64.2 million versus $75.8 million, and diluted EPS was $4.46 compared with $5.00. Segment revenue was $407.7 million at VITAS and $217.2 million at Roto‑Rooter.
For the first nine months, revenue reached $1.89 billion (vs. $1.79 billion) with net income of $188.5 million (vs. $211.7 million). Cash from operations was $254.7 million, supporting $253.5 million of share repurchases year‑to‑date, including $180.8 million in Q3. Cash was $129.8 million, and approximately $404.5 million remained available under the revolving credit facility. The company paid a $0.60 per share dividend in Q3; shares outstanding were 14,164,195 as of September 30, 2025. In VITAS, an Administrative Law Judge largely upheld higher‑level‑of‑care billings; the Medicare Administrative Contractor refunded the previously deposited amount, reducing the overpayment to a de minimis figure. Board repurchase authorization remaining was $301.8 million.
Chemed Corporation filed a current report stating that on October 28, 2025 it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company notes that this press release is furnished as Exhibit 99 to the report, making the detailed quarterly results available through that exhibit.
Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.
The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.
Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.
Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
